Company Mayne Pharma Group Limited

Equities

MYX

AU000000MYX0

Pharmaceuticals

Delayed Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
7.24 AUD +0.28% Intraday chart for Mayne Pharma Group Limited +3.43% +17.72%

Business Summary

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing generic pharmaceuticals. The Company operates through three segments: International, Branded Products Division (BPD) and Portfolio Products Division (PPD). Its International segment manufactures and sells branded and generic pharmaceutical product globally and the provision of contract development and manufacturing services to third party customers. The BPD segment distributes medically differentiated specialty products in United States. The PPD segment distributes established products (branded and generic) in the United States on a portfolio basis. The Company's products include Doxycycline Capsules, Oxycodone IR Tablets, Erythromycin Capsules and others.

Number of employees: 967

Sales per Business

AUD in Million2022Weight2023Weight Delta
International
35.2 %
54 12.8 % 65 35.2 % +19.01%
Branded Products Division
33.7 %
11 2.5 % 62 33.7 % +485.69%
Portfolio Products Division
31.0 %
269 63.3 % 57 31.0 % -78.82%

Sales per region

AUD in Million2022Weight2023Weight Delta
United States
67.8 %
371 87.3 % 124 67.8 % -66.44%
Australia and New Zealand
22.4 %
34 7.9 % 41 22.4 % +22.24%
Canada
5.4 %
9 2.1 % 10 5.4 % +9.62%
Asia
2.4 %
5 1.1 % 4 2.4 % -9.86%
Europe and Other
2.0 %
6 1.5 % 4 2.0 % -42.36%

Managers

Managers TitleAgeSince
Chief Executive Officer - 22-09-30
Director of Finance/CFO - 22-08-28
Chief Tech/Sci/R&D Officer - 14-12-31
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - -
Investor Relations Contact - -
Human Resources Officer - -
General Counsel - -
Corporate Officer/Principal - -
Corporate Officer/Principal - 20-03-25

Members of the board

Members of the board TitleAgeSince
Chairman 70 18-05-29
Director/Board Member 59 18-06-27
Chief Executive Officer - 22-09-30
Director/Board Member 58 22-01-31
Director/Board Member 67 14-08-25
Director/Board Member - Nov. 29
Director/Board Member 64 22-03-22
Director/Board Member - 22-08-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 81,245,827 57,414,136 ( 70.67 %) 0 70.67 %

Shareholders

NameEquities%Valuation
Viburnum Funds Pty Ltd.
7.556 %
6,428,268 7.556 % 28 M $
5,292,066 6.221 % 23 M $
Rubric Capital Management LP
5.121 %
4,356,426 5.121 % 19 M $
Lazard Asset Management Pacific Co.
4.985 %
4,240,774 4.985 % 19 M $
4,221,815 4.963 % 19 M $
Gft 2 Co. Pty Ltd.
1.523 %
1,295,569 1.523 % 6 M $
1,280,211 1.505 % 6 M $
Ivl Group Ltd.
0.9404 %
800,000 0.9404 % 4 M $
Vivnat (Curtin) Pty Ltd.
0.8816 %
750,000 0.8816 % 3 M $
Investors Mutual Ltd.
0.8428 %
717,000 0.8428 % 3 M $

Company contact information

Mayne Pharma Group Ltd.

1538 Main North Road Salisbury South

5106, Salisbury

+61 8 8209 2666

http://www.maynepharma.com
address Mayne Pharma Group Limited(MYX)